|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM278077668 |
003 |
DE-627 |
005 |
20231225015730.0 |
007 |
cr uuu---uuuuu |
008 |
231225s2017 xx |||||o 00| ||chi c |
024 |
7 |
|
|a 10.3760/cma.j.issn.0578-1310.2017.11.011
|2 doi
|
028 |
5 |
2 |
|a pubmed24n0926.xml
|
035 |
|
|
|a (DE-627)NLM278077668
|
035 |
|
|
|a (NLM)29141316
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a chi
|
100 |
1 |
|
|a Huang, K
|e verfasserin
|4 aut
|
245 |
1 |
2 |
|a A clinical analysis of micafungin treatment of pulmonary invasive fungal infection in pediatric patients with acute leukemia or post hematopoietic stem cells transplantation
|
264 |
|
1 |
|c 2017
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 23.03.2018
|
500 |
|
|
|a Date Revised 02.12.2018
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Objective: To investigate the efficacy and safety of micafungin (MCF) for pulmonary invasive fungal disease (PIFD) in pediatric patients with acute leukemia or post hematopoietic stem cells transplantation. Method: Twenty-five neutropenic PIFD children with acute leukemia or post hematopoietic stem cells transplantation in Sun Yat-sen Memorial Hospital of Sun Yat-sen University were selected from January 2012 to June 2015, including 12 males and 13 females, age range 2-15 (average 6.2±2.0) years. There were 12 cases of acute leukemia (AL) after chemotherapy, 4 cases of acute leukemia (AL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and 9 cases of β-thalassemia major after allo-HSCT. All children received MCM for the treatment of PIFD, the dosage of MCM was 3-4 mg/ (kg·d) , once a day. The children received 2 to 6 courses of treatment, individually with a course of 7 days. 1, 3-β-D glucan assay (G test), galactomannan antigen test (GM test), high-resolution CT and the biochemical indexes for organ functions were closely monitored. Result: Twenty-five cases were diagnosed as PIFD, including 2 patients diagnosed as proven, 6 as probable and 17 as possible. Of the 25 cases, 1 was confirmed aspergillus by biopsy pathology and 1 was candida albicans by blood culture. The G and GM test with positive results was 5 and 2 respectively. Chest CT scans of the 25 cases had obvious lesions: air crescent sign and cavitation in 4 cases, diffuse ground glass change in 9 cases, double lung scattered patchy, small nodules and cord like high density shadow in 7 cases, unilateral or bilateral chest wall wedge-shaped consolidation edge in 5 cases and pleural effusion in 5 patients. The effective rate of MCF in treatment of PIFD was 68% (17/25), including 13 cases cured, 4 cases improved, 4 cases were improved clinically and in 4 cases the treatment was ineffective. Eight cases were effective in MCF monotherapy group (12 cases) and nine were effective in MCF combined therapy group(13 cases), respectively. Side-effects including allergies, gastrointestinal side effects, electrolyte disturbances, impairment of liver and kidney function, and myelosuppression were not found in those children treated with MCF. Conclusion: Micafungin is effective and safe in the treatment of pulmonary invasive fungal disease in pediatric patients with acute leukemia or post hematopoietic stem cell transplantation
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Child
|
650 |
|
4 |
|a Hematopoietic stem cell transplantation
|
650 |
|
4 |
|a Leukemia
|
650 |
|
4 |
|a Mycoses
|
650 |
|
7 |
|a Echinocandins
|2 NLM
|
650 |
|
7 |
|a Lipopeptides
|2 NLM
|
650 |
|
7 |
|a Micafungin
|2 NLM
|
650 |
|
7 |
|a R10H71BSWG
|2 NLM
|
700 |
1 |
|
|a Qiu, K Y
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Deng, L L
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Fang, J P
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Li, Y
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Guo, H X
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Zhou, D H
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Zhonghua er ke za zhi = Chinese journal of pediatrics
|d 1960
|g 55(2017), 11 vom: 02. Nov., Seite 844-847
|w (DE-627)NLM136249191
|x 0578-1310
|7 nnns
|
773 |
1 |
8 |
|g volume:55
|g year:2017
|g number:11
|g day:02
|g month:11
|g pages:844-847
|
856 |
4 |
0 |
|u http://dx.doi.org/10.3760/cma.j.issn.0578-1310.2017.11.011
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_20
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_31
|
912 |
|
|
|a GBV_ILN_39
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_50
|
912 |
|
|
|a GBV_ILN_61
|
912 |
|
|
|a GBV_ILN_65
|
912 |
|
|
|a GBV_ILN_69
|
912 |
|
|
|a GBV_ILN_70
|
912 |
|
|
|a GBV_ILN_72
|
912 |
|
|
|a GBV_ILN_120
|
912 |
|
|
|a GBV_ILN_130
|
912 |
|
|
|a GBV_ILN_227
|
912 |
|
|
|a GBV_ILN_244
|
912 |
|
|
|a GBV_ILN_285
|
912 |
|
|
|a GBV_ILN_294
|
912 |
|
|
|a GBV_ILN_350
|
912 |
|
|
|a GBV_ILN_665
|
912 |
|
|
|a GBV_ILN_813
|
951 |
|
|
|a AR
|
952 |
|
|
|d 55
|j 2017
|e 11
|b 02
|c 11
|h 844-847
|